High seroreactivity against SARS-CoV-2 Spike epitopes in a pre SARS-CoV-2 cohort: implications for antibody testing and vaccine design

Kaia Palm, Mariliis Jaago, Annika Rähni, Nadežda Pupina, Arno Pihlak, Helle Sadam, Annela Avarlaid, Anu Planken, Margus Planken, Liina Haring, Eero Vasar, Miljana Baćević, France Lambert, Eija Kalso, Pirkko Pussinen, Pentti J. Tienari, Antti Vaheri, Dan Lindholm, Tõnis Timmusk, Amir M Ghaemmaghami
doi: https://doi.org/10.1101/2020.05.18.20105189

Article Information

doi 
https://doi.org/10.1101/2020.05.18.20105189
History 
  • May 22, 2020.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Kaia Palm1,*,#,
  2. Mariliis Jaago1,2,*,
  3. Annika Rähni1,2,
  4. Nadežda Pupina1,
  5. Arno Pihlak1,
  6. Helle Sadam1,2,
  7. Annela Avarlaid2,
  8. Anu Planken3,
  9. Margus Planken3,
  10. Liina Haring4,
  11. Eero Vasar5,6,
  12. Miljana Baćević7,
  13. France Lambert8,
  14. Eija Kalso9,
  15. Pirkko Pussinen10,
  16. Pentti J. Tienari11,
  17. Antti Vaheri12,
  18. Dan Lindholm13,14,
  19. Tõnis Timmusk1,2 and
  20. Amir M Ghaemmaghami15,#
  1. 1Protobios Llc, Tallinn, Estonia. Electronic address: kaia{at}protobios.com
  2. 2Department of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia;
  3. 3North Estonia Medical Centre Foundation, Tallinn, Estonia;
  4. 4Institute of Clinical Medicine, University of Tartu, Psychiatry Clinic of Tartu University Hospital, Estonia;
  5. 5Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia;
  6. 6Center of Excellence for Genomics and Translational Medicine, University of Tartu, Tartu, Estonia;
  7. 7Dental Biomaterial Research Unit (d-BRU), Faculty of Medicine, University of Liege, Liege, Belgium;
  8. 8Department of Periodontology and Oral Surgery, Faculty of Medicine, University of Liege, Belgium;
  9. 9Department of Anaesthesiology, Intensive Care and Pain Medicine, Helsinki Uiversity Hospital and Department of Pharmacology and SleepWell Research Programme, University of Helsinki, Helsinki, Finland;
  10. 10Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland;
  11. 11Department of Neurology, Neurocenter, Helsinki University Hospital, and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland;
  12. 12Department of Virology, Medicum, University of Helsinki, Finland;
  13. 13Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland;
  14. 14Minerva Foundation Institute for Medical Research, Helsinki, Finland;
  15. 15Immunology and Immuno-Bioengineering Group, School of Life Science, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, United Kingdom. Electronic address: Amir.Ghaemmaghami{at}nottingham.ac.uk
  1. ↵#Correspondence to Kaia Palm or Amir Ghaemmaghami; email: amg{at}nottingham.ac.uk

  1. ↵* These authors contributed equally to the work.

Back to top
Posted May 22, 2020.
Download PDF

Supplementary Material

Data/Code
Email
High seroreactivity against SARS-CoV-2 Spike epitopes in a pre SARS-CoV-2 cohort: implications for antibody testing and vaccine design
Kaia Palm, Mariliis Jaago, Annika Rähni, Nadežda Pupina, Arno Pihlak, Helle Sadam, Annela Avarlaid, Anu Planken, Margus Planken, Liina Haring, Eero Vasar, Miljana Baćević, France Lambert, Eija Kalso, Pirkko Pussinen, Pentti J. Tienari, Antti Vaheri, Dan Lindholm, Tõnis Timmusk, Amir M Ghaemmaghami
medRxiv 2020.05.18.20105189; doi: https://doi.org/10.1101/2020.05.18.20105189
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area